The two-groups model and the false discovery rate
A common model for p-values from multiple hypothesis tests is the "two-groups" model [1] , where the p-values are assumed to be drawn from the mixture distribution:
where π 0 is the proportion of p-values corresponding to tests where the null hypothesis is true, f 0 (·) is the density of the p-values under the null hypotheses and f 1 (·) is the density of p-values under the alternative hypothesis. In general, each test may have a corresponding null and alternative distribution, in which case both f 0 and f 1 may be represented by mixture distributions. This model is frequently used in genomics [2] , or brain imaging studies [3] , where thousands of variables are measured simultaneously with the goal of estimating the statistical significance of a group of variables [4] . This model simultaneously estimates π 0 , the fraction of results that are drawn from the null distribution. Alternatively, 1 − π 0 represents the fraction of p-values from the alternative distribution.
A modified two-groups model for p-values < 0.05
It is assumed that p-values are distributed U(0, 1) under the null hypothesis [5] , so f 0 (p) = 1[p ∈ (0, 1)]. A common choice for parameterizing the alternative distribution is the Beta distribution β(a, b), with f 1 (p) = β(p; a, b) [6] . But the reported p-values in the published literature do not represent the complete distribution of p-values from all hypotheses tested. Indeed, most p-values reported in abstracts are less than 0.05, the conventional threshold for statistical significance used by most journals (p ≤ 0.05 for 81% of the p-values in our data). So we define a new two-groups model for p-values reported in the scientific literature conditional on the event {p ≤ 0.05}: , both by properties of conditional distributions [7] .
We can fit the modified two groups model (1) using the EM-algorithm [8] . First, we introduce the (unobserved) indicator z i which is equal to 1 if the pvalue corresponds to a null hypothesis and 0 if the p-value corresponds to the alternative hypothesis. We can then write the complete data likelihood (for m total p-values) as:
where the indicator for the null distribution has been suppressed for ease of notation. This is a standard two-groups mixture model and can be fit with the EM-algorithm directly.
Rounding and truncation of p-values
There are two key issues that prevent direct use of the likelihood (2). The first is that reported p-values are frequently truncated, so if the calculated p-value is p = 1.134 × 10 −12 then the reported p-value is often p < 0.001. We treat these observations as left-censored and introduce the indicator function δ i , which is equal to 1 if p-value i is truncated and 0 otherwise. Since truncated p-values are reported with < or ≤ signs in the literature, the truncation indicator is directly observed. Following the usual approach for modeling parametric survival data [9] (with time running backward) we can modify equation (2) to deal with the contribution of the truncated p-values:
The second issue is that reported p-values are frequently rounded to two significant digits, so if the calculated p-value is p = 0.033333, the reported pvalue is often p = 0.03. Histograms of the mined p-values show clear spikes at the values 0.01, 0.02, 0.03, 0.04, and 0.05 ( Figure 3 ). Any p-value that is reported exactly as a value with only two significant digits was assumed to be rounded.
We introduce a second indicator, r i , which is equal to 1 if the p-value is rounded and 0 otherwise. We consider the rounding indicator, like the censored indicator, to be observed. We then modify the likelihood to include a multinomial term for the rounded p-values with values at 0, 0.01, 0.02, 0.03, 0.04 and 0.05. The probability of each value under the null and alternative hypothesis are calculated by integrating the null (or alternative) distribution over the interval of values that round to the two digit number [10, 11] . For example, under the null, the probability of a reported value of 0.01 is:
0.015 0.005 f 0 (x)dx. Using this framework we can define the probabilities of each rounded value under the null and alternative hypotheses:
where k = 0, 1, 2, 3, 4, 5, the upper and lower bounds are defined by the rounding regions, and j = 0, 1 for the null and alternative hypotheses, respectively. Since these q k j are conditional on whether the observed p-values are null or alternative, the unconditional probabilities for this multinomial distribution are π j q k j , where
For each of the k values, we observe the number of p-values rounded to that value, which we denote n = (n 0 , n 1 , n 2 , n 3 , n 4 , n 5 ) and we also introduce a second, unobserved, variable equal to the number of observations from the null distribution corresponding to each value, which we denote n 0 = (n 
. With the addition of these variables, the complete data likelihood is:
An EM Algorithm for fitting the two-groups model
To estimate the parameters in model (3) we apply the EM algorithm. The first step is to calculate the expected value of the complete data log-likelihood conditional on the observed data. The log-likelihood is:
The log-likelihood is linear in the unobserved variables z i and n 0 , so to calculate the expectation of the complete-data log-likelihood we calculate the expectation of these variables conditional on the observed data.
• If the p-value is not truncated or rounded (δ i = 0, r i = 0) the expectation is:
• If the p-value is truncated but not rounded (δ i = 1, r i = 0) the expectation is:
Similarly we can calculate the expectation of each element of n 0 as
M-step
The log-likelihood can be maximized directly for the parameter π 0 by solving the equation:
which leads to the estimatê
k=0 n k The integrals in q j mean that the log-likelihood can not be directly maximized for the parameters (a, b). At each step of the EM algorithm, we numerically maximize the part of the log-likelihood equation that depends on (a, b),
with respect to (a, b) using the mle R function in the stats4 package.
For the results in our paper, the E-step and M-step are iterated 100 times. We applied the EM-algorithm to calculate the false discovery rate in each journal in each year. We also applied the EM-algorithm to calculate the rate of false discovery rate in each journal considering all years and to calculate the overall false discovery rate.
2 Bootstrap standard errors for the false discovery rate
We calculated bootstrap standard errors for the estimatesπ 0 by sampling with replacement sets of variables {(p i , δ i , r i )} of size m, the number of observed p-values, and applying the EM algorithm to each bootstrap sample. The bootstrapped standard deviation is an estimate of the standard deviation of the false discovery rate estimates [12] .
p-value reporting and the conditional p-value model
Our analysis is focused on estimating a false discovery rate across multiple studies. In this case, not all p-values may be reported. The critical component of conservatively estimating the false discovery rate is that the null distribution is accurately modeled. The following proposition makes clear the conditions under which our conditional model is appropriate for the null distribution of the sampled p-values. Proof If the null p-values are correctly calculated then p i ∼ U (0, 1). The distribution of the reported p-values less than α is f (p i |y i = 1,
In particular, Proposition 1 implies that the following cases result in accurate models of the null distribution using our proposed conditional model: (1) investigators report all p-values less than α as significant, (2) investigators report the first p-value they observe less than α as significant, (3) investigators report all p-values less than α as significant, only when their intuition suggests they should report that p-value, as long as that intuition is based on separate biological knowledge that the result is interesting independent of the p-value. However, there are some cases where the conditional model is not theoretically correct. For example, if investigators calculate many p-values and only report the minimum p-value.
Collecting p-values from reported studies
Our p-value data was collected using the code in the supplementary R script getPvalues.R. The script scrapes the Pubmed website for abstracts corresponding to papers published in The American Journal of Epidemiology, The Journal of the American Medical Association, The New England Journal of Medicine, The British Medical Journal, and The Lancet. These p-values were scraped from http://www.ncbi.nlm.nih.gov/pubmed/ on January 24, 2012, a small amount of manual correction was performed and is detailed in the R script.
Any p-values that were calculated as NA were removed from the analysis and the analysis is based on only the p-values less than 0.05 as described above.
Collecting data on the number of submissions to medical journals
We directly contacted the editors of The American Journal of Epidemiology, The Journal of the American Medical Association, The New England Journal of Medicine, The British Medical Journal, and The Lancet, who supplied the data on the number of submitted manuscripts to their respective journals.
Manual validation of data for a random set of abstracts
Ten Pubmed ID's were selected using the random number generator in the accompanying R script. Here we report the collected P-values and abstracts for these Pubmed ID's. P-values appearing in abstracts are highlighted in blue. . At doses greater than 30 Gy, a fall in the dose-response relation was seen. Both the increased and decreased risks were more pronounced in those diagnosed with a first primary malignant disease before age 10 years than in those older than 10 years. Furthermore, the fall in risk remained when those diagnosed with Hodgkin's lymphoma were excluded. Chemotherapy for the first cancer was not associated with thyroid-cancer risk, and it did not modify the effect of radiotherapy. 29 (42%) cases had a first diagnosis of Hodgkin's lymphoma compared with 49 (19%) controls. 11 (42%) of those who had Hodgkin's lymphoma had subsequent thyroid cancers smaller than 1 cm compared with six (17%) of those who had other types of childhood cancer (p=0.07).
INTERPRETATION: The reduction in radiation dose-response for risk of thyroid cancer after childhood exposure to thyroid doses higher than 30 Gy is consistent with a cell-killing effect. Standard long-term follow-up of patients who have had Hodgkin's lymphoma for detection of thyroid cancer should also be undertaken for survivors of any cancer during childhood who received radiotherapy to the thorax or head and neck region. PARTICIPANTS: Pregnant women, breastfeeding mothers, and babies registered with 14 of 66 eligible clusters of general practices (localities) in Scotland that routinely collect breastfeeding outcome data.
INTERVENTION: Localities set up new breastfeeding groups to provide population coverage; control localities did not change group activity.
MAIN OUTCOME MEASURES: Primary outcome: any breast feeding at 6-8 weeks from routinely collected data for two pre-trial years and two trial years. Secondary outcomes: any breast feeding at birth, 5-7 days, and 8-9 months; maternal satisfaction.
RESULTS: Between 1 February 2005 and 31 January 2007, 9747 birth records existed for intervention localities and 9111 for control localities. The number of breastfeeding groups increased from 10 to 27 in intervention localities, where 1310 women attended, and remained at 10 groups in control localities. No significant differences in breastfeeding outcomes were found. Any breast feeding at 6-8 weeks declined from 27% to 26% in intervention localities and increased from 29% to 30% in control localities (P=0.08, adjusted for pre-trial rate). Any breast feeding at 6-8 weeks increased from 38% to 39% in localities not participating in the trial. Women who attended breastfeeding groups were older (P < 0.001) than women initiating breast feeding who did not attend and had higher income (P=0.02) than women in the control localities who attended postnatal groups. The locality cost was pound13 400 (euro14 410; $20 144) a year.
CONCLUSION: A policy for providing breastfeeding groups in relatively deprived areas of Scotland did not improve breastfeeding rates at 6-8 weeks. The costs of running groups would be similar to the costs of visiting women at home. 4. Pubmed ID: 11907289, Collected P-value(s): 0.001
Endothelin-1 is a potent vasoconstrictor and smooth-muscle mitogen. In a preliminary study, the orally administered dual endothelin-receptor antagonist bosentan improved exercise capacity and cardiopulmonary hemodynamics in patients with pulmonary arterial hypertension. The present trial investigated the effect of bosentan on exercise capacity in a larger number of patients and compared two doses.
METHODS: In this double-blind, placebo-controlled study, we randomly assigned 213 patients with pulmonary arterial hypertension (primary or associated with connective-tissue disease) to receive placebo or to receive 62.5 mg of bosentan twice daily for 4 weeks followed by either of two doses of bosentan (125 or 250 mg twice daily) for a minimum of 12 weeks. The primary end point was the degree of change in exercise capacity. Secondary end points included the change in the Borg dyspnea index, the change in the World Health Organization (WHO) functional class, and the time to clinical worsening.
RESULTS: At week 16, patients treated with bosentan had an improved sixminute walking distance; the mean difference between the placebo group and the combined bosentan groups was 44 m (95 percent confidence interval, 21 to 67; P < 0.001). Bosentan also improved the Borg dyspnea index and WHO functional class and increased the time to clinical worsening.
CONCLUSIONS: The endothelin-receptor antagonist bosentan is beneficial in patients with pulmonary arterial hypertension and is well tolerated at a dose of 125 mg twice daily. Endothelin-receptor antagonism with oral bosentan is an effective approach to therapy for pulmonary arterial hypertension.
5.
Pubmed ID: 19741227, Collected P-value(s): 0.02,0.02 BACKGROUND: Progressive multifocal leukoencephalopathy (PML) occurs in a fraction of patients with multiple sclerosis who were treated with natalizumab.
Most adults who are infected with the JC virus, the etiologic agent in PML, do not have symptoms. We sought to determine whether exposure to natalizumab causes subclinical reactivation and neurotropic transformation of JC virus.
METHODS: We followed 19 consecutive patients with multiple sclerosis who were treated with natalizumab over an 18-month period, performing quantitative polymerase-chain-reaction assays in blood and urine for JC virus reactivation; BK virus, a JC virus-related polyomavirus, was used as a control. We determined JC virus-specific T-cell responses by means of an enzyme-linked immunospot assay and antibody responses by means of an enzyme-linked immunosorbent assay and analyzed JC virus regulatory-region sequences.
RESULTS: After 12 months of natalizumab therapy, the prevalence of JC virus in the urine of the 19 patients increased from a baseline value of 19% to 63% (P=0.02). After 18 months of treatment, JC virus was detectable in 3 of 15 available plasma samples (20%) and in 9 of 15 available samples of peripheralblood mononuclear cells (60%) (P=0.02). JC virus regulatory-region sequences in blood samples and in most of the urine samples were similar to those usually found in PML. Conversely, BK virus remained stable in urine and was undetectable in blood. The JC virus-specific cellular immune response dropped significantly between 6 and 12 months of treatment, and variations in the cellular immune response over time tended to be greater in patients in whom JC MAIN OUTCOME MEASURES: General improvement, number of nights waking up due to symptoms, and severity of symptoms.
RESULTS: In the intention-to-treat analyses, surgery was more effective than splinting on all outcome measures. The success rates (based on general improvement) after 3 months were 80% for the surgery group (62/78 patients) vs 54% for the splinting group (46/86 patients), which is a difference of 26% (95% confidence interval [CI], 12%-40%; P¡.001). After 18 months, the success rates increased to 90% for the surgery group (61/68 patients) vs 75% for the splinting group (59/79 patients), which is a difference of 15% (95% CI, 3%-27%; P =.02). However, by that time 41% of patients (32/79) in the splint group had also received the surgery treatment.
CONCLUSION: Treatment with open carpal tunnel release surgery resulted in better outcomes than treatment with wrist splinting for patients with CTS.
7. Pubmed ID: 12241661, Collected P-value(s): 0.0001
Urotensin II has vasoconstrictive and negative inotropic effects, suggesting a possible role in circulatory regulation and pathophysiology of heart failure. We developed a sensitive specific RIA and measured plasma urotensin II in patients with heart failure and in controls. Plasma urotensin II was higher in heart failure patients (mean 3.9 pmol/L [SD 1.4]; than in controls (1.9 pmol/L [0.9]; p < 0.0001). The role of urotensin II in heart failure, however, has yet to be defined.
8. Pubmed ID: 12181103, Collected P-value(s): 0.0001
In 1993-1995, the authors evaluated risk factors for elevated blood and bone lead levels in 264 Boston, Massachusetts, area women previously selected for a casecontrol study of lead and hypertension. Bone lead was measured at the tibia and patella with K x-ray fluorescence. Blood lead was analyzed by graphite furnace atomic absorption. Participants were aged 46-74 years and had mean lead levels of 3 (standard deviation, 2) micro g/dl (blood), 13 (standard deviation, 9) micro g/g (tibia), and 17 (standard deviation, 11) micro g/g (patella). In multivariate linear regression models, use of postmenopausal estrogen (inverse) and alcohol intake (positive) were significantly associated with blood lead levels. Both bone lead measures were significantly and positively associated with blood lead but only among postmenopausal women not using estrogen; for example, an increase from the first to the fifth quintile of tibia lead level (19 micro g/g) was associated with a 1.7-micro g/dl increase in blood lead (p = 0.0001) in this group. Older age and lower parity were associated with higher tibia lead; only age was associated with patella lead. The observed interaction of bone lead with estrogen status in determining blood lead supports the hypothesis that increased bone resorption, as occurs postmenopausally because of decreased estrogen production, results in heightened release of bone lead stores into blood.
9. Pubmed ID: 11943693, Collected P-value(s): 0.0001,0.02
Isoflavones are naturally occurring selective estrogen receptor modulators, with potential bone protective effects. To study the relation between soy isoflavone intake and bone mineral density (BMD), the authors analyzed baseline data from the Study of Women's Health Across the Nation, a US community-based cohort study of women aged 42-52 years. Their 1996-1997 analysis included AfricanAmerican (n = 497), Caucasian (n = 1,003), Chinese (n = 200), and Japanese (n = 227) participants. Genistein and daidzein intakes were highly correlated (r = 0.98); therefore, analyses were conducted by using genistein. Median intakes of genistein (measured in micrograms/day) by African Americans and Caucasians were too low to pursue relational analyses further. For Chinese and Japanese women, median genistein intakes were 3,511 and 7,151 microg/day, respectively. Ethnic-specific, linear models were used to predict BMD as a function of energyadjusted tertile of intake, controlled for relevant covariates. For Chinese women, no association between genistein and BMD was found. Premenopausal, but not perimenopausal, Japanese women whose intakes were greater had higher spine and femoral neck BMD. Adjusted mean spinal BMD of those in the highest tertile of intake was 7.7% greater than that of women in the lowest tertile (p = 0.02); femoral neck BMD was 12% greater in the highest versus the lowest tertile (p < 0.0001).
10. Pubmed ID: 14693873, Collected P-value(s): 0.0001,0.02,0.01,0.03,0.001
CONTEXT: Complicated, left-sided native valve endocarditis causes significant morbidity and mortality in adults. The presumed benefits of valve surgery remain unproven due to lack of randomized controlled trials.
OBJECTIVE: To determine whether valve surgery is associated with reduced mortality in adults with complicated, left-sided native valve endocarditis.
DESIGN AND SETTING: Retrospective, observational cohort study conducted from January 1990 to January 2000 at 7 Connecticut hospitals. Propensity analyses were used to control for bias in treatment assignment and prognostic imbalances.
PATIENTS: Of the 513 adults with complicated, left-sided native valve endocarditis, 230 (45%) underwent valve surgery and 283 (55%) received medical therapy alone.
MAIN OUTCOME MEASURE: All-cause mortality at 6 months after baseline.
RESULTS: In the 6-month period after baseline, 131 patients (26%) died. In unadjusted analyses, valve surgery was associated with reduced mortality (16% vs 33%; hazard ratio [HR], 0.43; 95% confidence interval [CI], 0.29-0.63; P < .001).
After adjustment for baseline variables associated with mortality (including hospital site, comorbidity, congestive heart failure, microbial etiology, immunocompromised state, abnormal mental status, and refractory infection), valve surgery remained associated with reduced mortality (adjusted HR, 0.35; 95% CI, 0.23-0.54; P < .02). In further analyses of 218 patients matched by propensity scores, valve surgery remained associated with reduced mortality (15% vs 28%; HR, 0.45; 95% CI, 0.23-0.86; P =.01). After additional adjustment for variables that contribute to heterogeneity and confounding within the propensity-matched group, surgical therapy remained significantly associated with a lower mortality (HR, 0.40; 95% CI, 0.18-0.91; P =.03). In this propensity-matched group, patients with moderate to severe congestive heart failure showed the greatest reduction in mortality with valve surgery (14% vs 51%; HR, 0.22; 95% CI, 0.09-0.53;P =.001).
CONCLUSIONS: Valve surgery for patients with complicated, left-sided native valve endocarditis was independently associated with reduced 6-month mortality after adjustment for both baseline variables associated with the propensity to undergo valve surgery and baseline variables associated with mortality. The reduced mortality was particularly evident among patients with moderate to severe congestive heart failure.
